Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Sparta to develop new camptothecin formulations

April 5, 1996

New daunorubicin derivative from P&U

April 5, 1996

Spartaject busulfan to enter phase I

April 5, 1996

FDA approves expanded labeling for Ethyol

March 15, 1996

Multidrug resistance modulator from Pfizer

March 15, 1996

Xenova to evaluate MDR modulator in phase I

March 15, 1996

MethylGene established to study antisense drugs for cancer indications

March 15, 1996

Eisai describes antitumor sulfonamide

March 15, 1996

OM-174 shows in vivo antitumor activity

March 15, 1996

Glaxo Wellcome reports antitumor drugs

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
ASH 2025: Tec-dara shines on ‘functional cure’ Majestec-3 MM data
BioWorld
Impressive results of a potential second-line combination treatment for multiple myeloma from the Majestec-3 trial of teclistamab plus daratumumab raised eyebrows...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...